Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.
Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.
This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.

开始日期2024-01-22

申办/合作机构

Imperial College London

NCT05625932 / Recruiting临床3期IIT

Prophylaxis of Venous Thromboembolic Disease With Low Molecular Weight (LMWH) (TINzaparin) in Patients With Metastatic Colorectal Cancer Who Start the First Line of Treatment.

Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population.
PROTINCOL is a randomized, open label, non placebo-controlled, low intervention, and phase III clinical trial that will recruit patients with mCRC. The study hypothesizes that prophylaxis with Tinzaparin could prevent the appearance of symptomatic and incidental VTE.
All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria. Enrolled patients are randomized in a 1:1 ratio (stratifying by BRAF/RAS, resection of primary tumor, and anti-angiogenic first-line treatment) to: control arm (no interventions related to VTE risk and no placebo) or experimental arm (prophylactic Tinzaparin at a fixed dose of 4500 IU/day in patients with up to 80kg, 6000 IU/day for those between 80-100 kg, or 8000 IU/day for those >100kg). Treatment is scheduled for a maximum period of 4 months. Treatment could be stopped earlier in case of unacceptable toxicity, patient consent withdrawal, physician criteria or end of study. Patients will undergo tumor and VTE assessments according to standard clinical practice.
The main objective of the study is to evaluate the efficacy of tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary objectives include the associations between VTE events and tumor characteristics (i.e. laterality, RAS/BRAF mutations) or management (i.e. surgery or treatment with anti-angiogenic or anti-EGFR agents), cancer-specific survival outcomes, safety, the incidence of bleeding events, and patient-reported quality of life. The trial includes also a translational exploratory analysis to assess the predictive value of risk assessment models and genetic risk scores, their evolution through the study and microsatellite instability or other biomarkers.

开始日期2023-03-02

申办/合作机构

Leo Pharma, Inc.

NCT05255003 / Recruiting临床4期IIT

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and/or cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts.
The investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 4 weeks. Patients will be randomly assigned to one of the two treatment strategies: the full dose of blood thinners along with platelet transfusion or a reduced dose of blood thinners without platelet transfusion. The investigators will follow all patients for 90 days. If this pilot study is successful, it will help lead to a much larger trial, which will provide important information on the best treatment strategy in these patients.

开始日期2022-08-29

申办/合作机构

Ottawa Hospital Research Institute

100 项与亭扎肝素钠相关的临床结果

登录后查看更多信息

100 项与亭扎肝素钠相关的转化医学

登录后查看更多信息

100 项与亭扎肝素钠相关的专利（医药）

登录后查看更多信息

509

项与亭扎肝素钠相关的文献（医药）

2024-11-01·European journal of hospital pharmacy : science and practice

Questions around a case ofin uterothrombosis in a premature child, concerning the management of anticoagulant treatments

Article

作者: Gerard, Delphine ; Prot-Labarthe, Sonia ; Simon, Laure ; Ternisien, Catherine ; Callies, Arnaud

We report the case of a preterm infant presenting a thrombosis, discovered on ultrasound at 22 weeks of gestational age and confirmed at birth following additional examinations. We describe the anticoagulant treatment of this patient by intravenous enoxaparin, tinzaparin and rivaroxaban, from questioning to practice.

2024-07-01·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study

Article

作者: Delavenne, Xavier ; Mansour, Alexandre ; Maucorps, Laure ; Pontis, Adeline ; Bouzille, Guillaume ; Caribotti, Charlène ; Mahé, Guillaume ; Gueret, Pierre ; Cardiet, Isabelle ; Mismetti, Patrick ; Gouin-Thibault, Isabelle ; Pierre-Jean, Morgane ; Nédelec-Gac, Fabienne ; Vannier, Stéphane ; Frouget, Thierry ; Behar, Nathalie ; Ballerie, Alice

BACKGROUND:

Tinzaparin could be easier to manage than unfractionated heparin in patients with severe renal impairment. However, clinical and pharmacologic data regarding its use in such patients are lacking.

OBJECTIVES:

The aims of this study were to determine, in patients with estimated glomerular filtration rate (eGFR) of <30 mL.min⁻¹, tinzaparin pharmacokinetics (PK) parameters using a population PK approach and bleeding and thrombotic complications.

METHODS:

We performed a retrospective observational single-center study, including in-patients with eGFR of <30 mL.min⁻¹ receiving prophylactic (4500 IU.d⁻¹) or therapeutic (175 IU.kg⁻¹.d⁻¹) tinzaparin. Measured anti-Xa levels were analyzed using a nonlinear mixed-effects modeling approach. Individual predicted tinzaparin exposure markers at steady state were calculated for each patient and dosing regimen. The PK was also evaluated through Monte Carlo simulations based on the final covariate model parameter estimates.

RESULTS:

Over a 22-month period, 802 tinzaparin treatment periods in 623 patients were analyzed: two-thirds received a prophylactic dose, 66% had an eGFR of <20 mL.min⁻¹, and 25% were on renal replacement therapy. In patients for whom anti-Xa measurements were performed (n = 199; 746 values), PK parameters, profiles, and maximum plasma concentrations were comparable with those in patients without renal impairment or in healthy volunteers. In the whole population, major bleeding occurred in 2.4% and 3.5% of patients receiving prophylactic and therapeutic doses over a median 9- and 7-day treatment period, respectively. No patients had thrombotic complications.

CONCLUSION:

Tinzaparin PK parameters and profiles were not affected by renal impairment. This suggests that tinzaparin, at therapeutic or prophylactic dose, could be an alternative to unfractionated heparin in hospitalized patients with severe renal impairment.

2024-05-01·PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Structured benefit–risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer

Article

作者: Gouin‐Soboleva, Tatiana ; Granados, Denis ; Fazekas, Zita ; El‐Haddad, Chantal ; Djoudi, Yasmina ; Benito‐Garcia, Elizabeth ; Kürzinger, Marie‐Laure

Abstract:

Purpose:

Guidelines recommend low‐molecular‐weight heparins (LMWHs) for patients with cancer‐associated thrombosis. However, until recently, only dalteparin and tinzaparin were approved in the European Economic Area (EEA) for these patients. This study compares the benefit–risk profile of enoxaparin with dalteparin and tinzaparin for the extended treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrence in adult patients with active cancer.

Methods:

A semi‐quantitative structured benefit–risk assessment was conducted for the label‐extension application of enoxaparin based on the benefit–risk action team descriptive framework: define decision context; determine key benefit and risk outcomes; identify data sources; extract data; interpret results.

Results:

The key benefits were defined as reduced all‐cause mortality and venous thromboembolism (VTE) recurrence (including symptomatic DVT, fatal PE or non‐fatal PE); the key risks were major and non‐major bleeding of clinical significance, and heparin‐induced thrombocytopenia (HIT). Enoxaparin demonstrated comparable effects for the reduction of VTE recurrence and all‐cause mortality versus other EEA‐approved LMWHs (dalteparin, tinzaparin). There was no evidence of a significant difference between enoxaparin and the comparator groups with regard to incidence of major and non‐major bleeding. The data on HIT were too limited to assess the difference between the two groups.

Conclusions:

The assessment demonstrated a favourable benefit–risk profile for enoxaparin similar to that of other EEA‐approved LMWHs for the treatment of DVT and PE and the prevention of recurrence in patients with active cancer and thus supported the label‐extension approval.

项与亭扎肝素钠相关的新闻（医药）

2023-11-06

·PRNewswire

Global Antithrombotic/Anticoagulant Drugs Market Set to Reach $46.2 Billion by 2028 with a 7.9% CAGR

DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global antithrombotic/anticoagulant drugs market is expected to reach $46.2 billion in 2028 from $31.6 billion in 2023 at a CAGR of 7.9%. This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market. This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028. Companies Mentioned Bayer AG Boehringer Ingelheim International GmbH Bristol Myers Squibb Daiichi Sankyo Co. Ltd. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Merck & Co. Inc. Pfizer Inc. Sanofi Report Includes 59 data tables and 35 additional tables Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19 A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration Profiles of the leading market players The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs: Recent innovations and the emergence of novel thrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-11.8%) and Innohep (-14.1%), have seen a significant decrease in the market. The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitors grows. The market for thrombin inhibitors is expected to grow at the highest CAGR of 8.1% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitors. An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Market Outlook Market Summary Chapter 3 Market Overview Overview of Cardiovascular Disease Coronary Artery Disease Atherosclerosis Angina (Angina Pectoris) Acute Myocardial Infarction Medical Management Lifestyle Changes Diet Modification Smoking Cessation Pharmaceuticals Anticoagulants and Antiplatelet Drugs Major Drivers Coagulation Factors Targeted to Reduce Cvd The Global Burden of Cardiovascular Disease 2030 Global Burden of Cardiovascular Disease The Global Economic Burden of Cardiovascular Disease Sales Performance of Major Drugs in 2022 Chapter 4 Global Market for Anticoagulant Drugs Overview Products Low Molecular Weight Heparin Oral Anticoagulants (Vitamin K Antagonists) Global Anticoagulant Drugs Market Forecast Chapter 5 Global Market for Antiplatelet Drugs Overview Products Oral Antiplatelets Global Antiplatelet Drugs Market Forecast Chapter 6 Global Market for Thrombin Inhibitors Overview Products Direct Thrombin Inhibitors Thrombolytic Agents Direct Factor Xa Inhibitors Global Thrombin Inhibitors Market Forecast Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region Overview North America Europe Asia-Pacific Rest of the World Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Introduction to ESG Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Key ESG Issues Consumer Attitudes Towards ESG Industry ESG Performance Analysis Case Study Concluding Remarks Chapter 9 Clinical Trials and Patent Landscape Clinical Trials Analysis Patent Analysis Patent by Assignee Chapter 10 M&A and Venture Funding Outlook Chapter 11 Competitive Landscape Chapter 12 Company Profiles Chapter 13 Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与亭扎肝素钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06398	亭扎肝素钠	B01AB10	DB06822

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺栓塞	美国	LEO Pharma A/S	2000-07-14
静脉血栓形成	美国	LEO Pharma A/S	2000-07-14
血栓形成	加拿大	Novo Nordisk Canada, Inc.	1994-12-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISTH2023	N/A	肾功能不全	623	Tinzaparin prophylactic dosage	艱簾衊壓顧襯齋觸製觸(顧鏇積糧繭繭憲積顧遞) = 餘鑰繭鑰簾蓋選願簾鹹繭遞鬱糧築簾醖夢獵蓋 (遞願網構選構網醖鏇願 )	-	2023-06-24
ISTH2023	N/A	肾功能不全	623	Tinzaparin therapeutic dosage	艱簾衊壓顧襯齋觸製觸(顧鏇積糧繭繭憲積顧遞) = 鏇壓構糧積繭糧醖築鬱繭遞鬱糧築簾醖夢獵蓋 (遞願網構選構網醖鏇願 )	-	2023-06-24
ISTH2022	N/A	浅表血栓性静脉炎	147	tinzaparin	壓構醖觸淵憲顧構鬱窪(構鹽鏇廠夢鹽鹽醖窪鹽) = 衊鑰遞艱鹹壓顧築範觸鏇鹹廠憲艱範齋獵觸積 (簾夢膚壓夢鏇窪餘艱衊 )	-	2022-07-09
ISTH2022	N/A	肥胖	-	Tinzaparin adjusted for actual body weight	顧鹹淵鏇鏇廠壓夢築獵(壓廠醖構蓋鹹壓築鹽網) = 築鏇鏇窪鏇膚鏇網醖鑰鬱簾築網鑰簾蓋齋繭鹹 (醖願簾遞夢廠選廠選繭, 0.20 ~ 0.31)	-	2022-07-09
Onco-CAST (ASCO2022)	临床4期	结直肠癌	175	Tinzaparin 8.000 Anti-Xa IU	艱鏇簾鹹遞餘夢壓製獵(簾簾鑰餘餘觸鬱糧餘壓) = 壓鑰遞觸獵糧範積淵襯範選艱壓構網襯繭獵積 (襯鏇構製鹽夢顧築製鹽, 2.3 ~ 8.8) 更多	-	2022-06-02
ASN2021	N/A	-	-	Tinzaparin	觸憲廠鏇獵鏇醖襯選夢(築選遞衊糧鹽鹹憲鏇膚) = 蓋築衊襯艱鬱醖夢築獵鏇簾窪觸窪鹹齋觸衊鏇 (糧餘鑰蓋選襯鑰襯廠襯 )	积极	2021-10-27
iCaLT study (ERS2021)	N/A	肺癌	60	Tinzaparin 0.5 ml, 10.000 Anti-Xa IU	廠範襯鏇鑰繭鏇齋網鏇(鬱簾製積網壓遞鏇廠製) = Low in patients with bleeding compared to others 網衊廠選範醖願鏇鏇鹽 (遞築淵遞醖遞糧觸醖鏇 )	积极	2021-09-05
PROSPERO CRD42020139413 (ISTH2020)	N/A	慢性肾病	1,831	Tinzaparin	範餘艱齋構願夢鏇積鑰(襯繭齋構廠顧顧顧觸壓) = 齋繭襯構願淵醖衊簾夢齋顧廠蓋壓蓋獵範艱糧 (襯膚糧憲廠製艱鹹窪構, (0.85 ~ 3.61)) 更多	-	2020-07-12
ISTH2020	N/A	静脉血栓栓塞	287	Weight-adjusted Tinzaparin	觸鑰壓遞醖鹽齋構顧衊(簾遞選醖遞觸範醖網選) = 網糧簾獵構網廠醖製簾艱壓網憲膚憲網積簾壓 (鹽築餘網獵糧顧衊鏇餘 )	-	2020-07-12
ISTH2020	N/A	静脉血栓栓塞	287	No prophylaxis or subcutaneous UFH	觸鑰壓遞醖鹽齋構顧衊(簾遞選醖遞觸範醖網選) = 網構襯製蓋鬱衊鑰鏇觸艱壓網憲膚憲網積簾壓 (鹽築餘網獵糧顧衊鏇餘 )	-	2020-07-12
TROPIQUE (ISTH2020)	N/A	血栓形成	-	Long-term tinzaparin treatment	蓋憲襯構簾齋簾齋夢鹹(齋範網襯餘範鹹積膚廠) = 製窪鹽窪鹽製廠遞鑰窪網蓋網夢遞襯蓋獵淵廠 (鬱鹽鹹廠蓋鏇廠襯壓顧 ) 更多	积极	2020-07-12
NCT00186745 (TRIVET, ASH2016) 人工标引	N/A	慢性肾病	148	Tinzaparin (1st measurement (Day 3-5))	築衊夢窪衊襯鹽襯衊憲(選鏇襯鏇簾壓醖壓範網) = 製遞蓋鹽鬱網夢積顧壓繭鑰憲積鏇鏇鹹艱窪積 (襯觸選鬱窪網繭壓窪餘, 0.22) 更多	积极	2016-12-02
NCT00186745 (TRIVET, ASH2016) 人工标引	N/A	慢性肾病	148	Tinzaparin (2nd measurement (Day 5-7))	築衊夢窪衊襯鹽襯衊憲(選鏇襯鏇簾壓醖壓範網) = 餘糧醖鹹積願鏇範淵膚繭鑰憲積鏇鏇鹹艱窪積 (襯觸選鬱窪網繭壓窪餘, 0.09) 更多	积极	2016-12-02